August 2, 2016 11:43 AM EDT
News Briefing

Pro­to­cols: Trou­bled Teles­ta ax­es staff in wake of FDA re­jec­tion; Evelo part­ners with Mayo re­searchers

John Carroll

Editor & Founder

Less than a year af­ter strik­ing a $137 mil­lion deal for the rights to Teles­ta’s blad­der can­cer drug MC­NA, Ipsen has de­cid­ed to punt the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times